By How Much Has Kimberly-Clark’s Revenue & EBITDA Changed In The Last 5 Years?

-5.03%
Downside
130
Market
123
Trefis
KMB: Kimberly-Clark logo
KMB
Kimberly-Clark

  • Revenue: Grew by 2% as decline in At-Home Tissue Products largely offset growth in other businesses
  • EBITDA: 9% EBITDA growth driven by business growth and margin expansion in At-Home Tissue Products

KMB-4

Have more questions on Kimberly-Clark? See the links below:

Relevant Articles
  1. Should You Pick Kimberly-Clark Stock At $120 After A Downbeat Q4?
  2. Is Kimberly-Clark Stock Fully Priced At $120?
  3. Which Is A Better Pick – Kimberly-Clark Stock Or IDEXX Laboratories?
  4. Which Is A Better Consumer Defensive Pick – Kimberly-Clark Or CL Stock?
  5. Is Kimberly-Clark Stock A Better Pick Over Its Industry Peer?
  6. Steady Revenue Growth Has Not Been Reflected In Kimberly-Clark’s Stock Price – Here’s Why

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Kimberly-Clark

Get Trefis Technology